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Abstract 
Background: The incidence, risk factors and outcomes associated with Contrast induced 
nephropathy (CIN) after Percutaneous Vascular Intervention (PVI) in contemporary med-
ical practice are largely unknown. 
Methods: A total of 13,126 patients undergoing PVI were included in the analysis. CIN 
was defined as an increase in serum creatinine from pre-PVI baseline to post-PVI peak Cr 
of ≥ 0.5 mg/dL.  
Results: CIN occurred in 3% (400 patients) of the cohort, and 26 patients (6.5%) re-
quired dialysis. Independent predictors of CIN were high and low body weight, diabetes, 
heart failure, anemia, baseline renal dysfunction, critical limb ischemia and a higher acui-
ty of the PVI procedure and a contrast dose that was greater than three times the calculat-
ed creatinine clearance (CCC) (adjusted OR 1.4, 95% CI: 1.1 to 1.8, p=0.003). CIN was 
strongly associated with adverse outcome including in-hospital death (adjusted OR 18.1, 
CI 10.7-30.6, p < 0.001), myocardial infarction (adjusted OR 16.2, CI 8.9-29.5, p < 
0.001), transient ischemic attack/stroke (adjusted OR 5.5, CI 3.2-14.9, p=0.001), vascular 
access complications (adjusted OR 3.4, CI 2.3-5, p < 0.001), and transfusion (adjusted 
OR 7, CI 5.4-9, p < 0.001). Hospital stay was longer in patients who developed CIN vs. 
those who did not.  
Conclusions: CIN is not an uncommon complication associated with PVI, can be reliably 
predicted from pre-procedural variables, including a contrast dose of greater than three 
times the CCC and is strongly associated with the risk of in-hospital death, MI, stroke, 
transfusion and increased hospital length of stay. 
Background 
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Acute decline in renal function is a well-known complication after cardiac and radiologic 
procedures that require contrast administration (1, 2). Among patients undergoing percu-
taneous coronary intervention (PCI), contrast induced nephropathy (CIN) is associated 
with increased morbidity, mortality, and healthcare cost (3-6). In patients with abnormal 
renal function at baseline, the incidence of CIN can be as high as 42% (1, 7). CIN may 
lead to transient or permanent need for hemodialysis, especially for high risk patients (3, 
8). Predictors of CIN in patients undergoing coronary intervention have been well charac-
terized, and include chronic kidney disease, diabetes, anemia and hemodynamic instabil-
ity (3-5, 9). CIN may also be related to the volume (10, 11) and type of contrast agent 
administered during the procedure, with high-osmolar contrast media carrying a greater 
risk (12), although CIN has been reported with both low osmolar and iso-osmolar con-
trast media administration (12, 13). 
 
Patients with peripheral vascular disease are increasingly being treated with percutaneous 
vascular intervention (PVI). While CIN would be an expected complication in this co-
hort, there is paucity of data on prevalence, predictors and outcome of CIN in patients 
undergoing PVI.  
 
This study was undertaken to determine the incidence of and risk factors for CIN, and 
assess the peri-procedural outcomes in patients who develop CIN after undergoing PVI. 
 
Methods 
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The study cohort for this analysis included patients undergoing PVI who were included in 
the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Vascular Interven-
tions Collaborative (BMC2 VIC). BMC2 VIC is a regional, multihospital, multidiscipli-
nary, physician-led collaboration among interventional cardiologists, interventional radi-
ologists and vascular surgeons designed to assess and improve quality of care and out-
comes of patients that undergo percutaneous peripheral vascular interventional (PVI) 
procedures (14, 15). Data on all patients undergoing PVI at the participating hospitals 
were collected using standardized data collection form. Baseline data included de-
mographics, clinical presentation, comorbidities, procedural, and angiographic character-
istics as well as medications used before, during and after the procedure, and in-hospital 
outcomes. All data elements have been prospectively defined, and the registry has been 
approved or the need for approval waived by IRBs at each of the participating institu-
tions. The data were collected by a trained and dedicated staff member and forwarded to 
the coordinating center. An audit of all major outcomes including death, stroke, myocar-
dial infarction, emergent vascular surgery, transfusion and CIN, and a random audit of 
5% of cases irrespective of outcome is performed at each participating institution to en-
sure data quality. 
 
Data were analyzed from 23052 consecutive PVI cases collected between January 1st 
2010 and December 31st 2013. Patients with end stage renal failure on dialysis, renal 
transplant, and/or missing pre or post-procedural creatinine values were excluded, as 
were patients who underwent hybrid procedure defined as an open surgical and PVI dur-
ing the same hospitalization. The final number of cases included for analysis was 13126.  
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CIN, the primary end point for this analysis, was defined as an increase in serum creati-
nine from baseline to post-PVI peak creatinine ≥ 0.5mg/dL (11). Peak creatinine was col-
lected at least 24 hours post-procedure, but varied depending on the length of stay. Sec-
ondary end points include need for transfusion, myocardial infarction, TIA/stroke and in-
hospital death. In-hospital death was defined as death from either cardiac or non-cardiac 
cause prior to discharge. Major adverse cardiac event (MACE) was defined as the com-
posite of death, myocardial infarction, transient ischemic attack (TIA) or stroke prior to 
discharge. 
 
Statistical Analyses 
Baseline characteristics, in-hospital treatments, and in-hospital complications of patients 
who developed CIN were compared with those who did not develop CIN. For descriptive 
purposes, we present categorical data as frequencies and percentages. The differences 
between groups were compared using χ² or Fisher exact tests, as appropriate. Continuous 
variables were reported as mean ± standard deviation (SD), and differences were com-
pared using independent t tests. We assessed the occurrence of CIN in patients based up-
on a ratio of contrast volume (CV) and calculated creatinine clearance (CCC), (CV/CCC) 
(11). 
Two separate multiple logistic regression models were constructed to assess 1) the asso-
ciation between CIN and other adverse outcomes, and 2) the relationship between pre-
procedural variables and CIN. For the first logistic regression model, different models 
were constructed for each adverse outcome using the predictor variables such as baseline 
characteristics (patient information and history), pre-procedural pharmacotherapy and 
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other clinically relevant variables in addition to CIN. Details can be found in Supplemen-
tary Table 1. From each constructed adverse outcome model, the exponential of the esti-
mated CIN’s coefficient and its 95% confidence interval were presented. Each model’s 
Hosmer-Lemeshow p-value and area under a receiver operating characteristic curve 
(AUC) were reported as model assessment for model fitting and prediction performance, 
respectively.  
 
In the second logistic regression model, the risk prediction model for CIN, we included 
the same pre-procedure predictor variables that were used in the adverse outcome models 
(see Supplement Table 1). In addition, we included a contrast volume variable to assess 
the impact of exceeding a contrast dose of 3X the calculated creatinine clearance (CCC), 
based on prior work (11) demonstrating an association between renal function adjusted 
contrast dose and occurrence of CIN among PCI patients. The CCC was calculated with 
the Cockcroft-Gault equation (19). The stepwise method based on Akaike information 
criteria (AIC) was applied for variable selection, and we presented all the variables that 
were selected. The Hosmer-Lemeshow p-value and AUC were reported as model assess-
ment. All calculations were performed using a statistical software R version 3.0.2. 
Results 
A total of 13126 patients who underwent PVI during the study period were included in 
the analysis. The overall incidence of CIN was 3.0% (n=400). Baseline demographics 
and clinical characteristics of CIN and non-CIN groups are shown in Table 1. Patients 
who developed CIN were, in general, higher risk patients; they were older, were more 
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likely to have co-morbidities including diabetes, congestive heart failure (CHF) and cere-
brovascular disease.  
 
The indications for the PVI procedure and types of interventions performed are summa-
rized in Table 1. Patients with critical limb ischemia (CLI) were noted to have signifi-
cantly higher incidence of CIN. Similarly, patients who underwent below the knee PVI 
(most of whom had CLI) more often developed CIN, while there was no difference in 
CIN when PVIs were performed in other vascular beds. Pre-procedure medical therapy in 
patients who developed CIN compared to those who did not is also highlighted in Table 1 
and was broadly similar.  
  
CIN was associated with significant morbidity and mortality (Figure 1). Compared with 
patients who did not develop CIN, those with incident CIN had significantly increased 
rates of death, myocardial infarction, transient ischemic attack or stroke, composite 
MACE, vascular complications, and transfusion. Development of CIN was also associat-
ed with greater than three times longer hospitalization.  
 
After adjusting for patient characteristics and pre-PVI pharmacotherapy, CIN remained a 
significant predictor of adverse in-hospital outcome associated with PVI (Figure 1). CIN 
was independently associated with post-PVI death, MACE, vascular access complication 
and transfusion. 
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The pre-PVI variables that were included in the developed post-PVI CIN risk model are 
shown in Table 2. Patient demographic and clinical factors that predicted the develop-
ment of CIN included; a history of diabetes, anemia, CHF and a pre-procedural CCC < 
60ml/min. Critical limb ischemia as an indication for the PVI procedure strongly predict-
ed development of CIN (11). We further evaluated the impact of CV utilized and the in-
teraction of CV and CCC. The risk of developing CIN was dramatically elevated in pa-
tients exceeding a CV to CCC ratio of 3 (adjusted OR: 1.4, 95% CI: 1.1 to 1.8, p = 
0.003). 
 
Discussion 
Risk factors for the development of, and outcomes associated with CIN have been well 
documented in the setting of PCI; however, there have been few published data on CIN 
associated with PVI. This is the first reported, large registry-based analysis of CIN in pa-
tients undergoing PVI. The central findings of this study are summarized in Figure 2. We 
found that CIN after PVI occurs in 3% of cases. However, when CIN does occur, it is as-
sociated with an extremely poor in-hospital outcome, including a greater than 25 fold in-
creased risk of death, an increased risk of MACE, transfusion, and an increased hospitali-
zation duration. Predictors of CIN in this real-world, contemporary cohort included pre-
PVI renal insufficiency, history of CHF, diabetes, anemia, and cerebrovascular disease. 
Patients with CLI as an indication for PVI and who undergo urgent or emergent PVI were 
also more likely to develop CIN. Use of higher volume of contrast normalized to baseline 
renal function was also strongly associated with CIN. 
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The health care implications of CIN are significant given the apparent relationship with 
patient morbidity, mortality and increased cost. Prior studies suggest that risk factors for 
acute renal insufficiency after contrast exposure include reduced baseline renal function, 
diabetes mellitus, heart failure, dehydration, previous diuretic use, hypoalbuminemia, in-
creased age, and increased contrast volume (1, 16, 17). The incidence of acute renal in-
sufficiency after PCI in patients with normal baseline renal function is approximately 2%; 
this rate increases to 20% to 30% in patients with a baseline creatinine greater than 
2mg/dL (16, 18). 
 
Chronic renal insufficiency (Cr > 1.5mg/dL or CCC < 60mL/min) has been consistently 
shown to increase the risk of CIN (3, 6, 16). Inadequate renal perfusion in the setting of 
CHF or hemodynamic instability is also associated with increased risk of CIN. While 
hemodynamic instability is not commonly a factor in PVI, other factors are similar and 
the presence of prior renal dysfunction, anemia, diabetes and total contrast volume impart 
an increased risk of CIN. In our analysis, CCC less than 60 mL/min was an important 
predictor of CIN with CCC less than 30 mL/min the strongest predictor of CIN.  
Age is a well-recognized independent predictor of CIN in observational studies (19). In 
our study, patients who developed CIN were of older age as compared to patients who 
did not develop CIN. These findings have been previously documented, where the inci-
dence of CIN in patients greater than 70 years who undergo cardiac catheterization is ap-
proximately 11% (6). However, in this cohort, age greater than 70 did not predict CIN on 
multivariable analysis. This finding is consistent with a previously published study that 
demonstrated the overall relative safety of PVI in elderly patients (20).  
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Diabetes mellitus is one of the strongest predictors of acute renal failure after coronary 
intervention (17), and is commonly found in patients requiring PVI. Anemia has also 
been identified as an independent risk factor in multivariable analysis, perhaps related to 
decreased oxygen delivery to tubular cells (21). In our study, both pre-procedure anemia 
and diabetes were noted to predict CIN. Hence, PVIs should be performed with extra cau-
tion in such patients and contrast dosing should be minimized. 
 
In our study, the CV/CCC ratio was directly related to the risk of CIN. This ratio has 
been validated in a large cohort of patients undergoing percutaneous coronary interven-
tion (11). Similar to the PCI cohort, we found that a CV/CCC of > 3 was associated with 
an increased risk of CIN.  
 
The choice of the contrast media used may also influence the risk of CIN. However, most 
of the excessive risk is associated with use of high osmolar contrast and recent data sug-
gest little difference in risk of CIN between most low osmolar and iso-osmolar contrast 
media (12, 13). Most PVIs in our cohort were performed with non-ionic, iso-osmolar 
contrast agents, with the balance of patients receiving non-ionic, low osmolar contrast. 
Given the preponderance of iso-osmolar contrast use in our study, it is likely that our 
study is underpowered to define the comparative renal safety of different contrast media 
for PVI.  
  
Strategies at reducing CIN include optimal case selection and risk stratification (18, 22), 
optimal hydration (23), minimizing contrast volume (10) and use of non-ionic contrast 
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agents (Iodixanol or low-osmolar contrast) (12, 24). In addition, utilization of carbon di-
oxide angiography has been associated with lower risk of CIN (25) and adequate periph-
eral arterial vessel visualization (26). We hope that a better understanding of risk factors 
for CIN in this population will help physicians better risk stratify patients and optimize 
preventive therapies. 
  
In this study, CIN was associated with prolonged in-hospital length of stay. The econom-
ic burden of contrast related nephropathy is high. Incremental in-hospital costs associated 
with CIN have been reported to be more than $10,000 based upon a length of stay differ-
ential between CIN and non-CIN patients of 3.75 days (27). Interestingly, in our study, 
the hospital length of stay of patients who suffered CIN post-PVI was 11.6 days and the 
incremental average length of stay with CIN in our cohort was 9.8 days suggesting that 
the cost differential is likely higher. Strategies designed to avoid contrast nephropathy, 
therefore, have the potential to not only improve outcome but to limit the economic bur-
den associated with this complication. 
 
CIN has not only been associated with increased morbidity, but increased in-hospital post 
procedure mortality. Rich et al (6) reported 183 patients with 70 or greater years of age 
undergoing cardiac catheterization- including patients with prior renal insufficiency 
(mean serum creatinine 1.3±0.7 mg/dL). In this study, 21/183 patients (11.5%) developed 
progressive renal dysfunction (serum creatinine elevation > 0.5mg/dL), which persisted 
in five of them (24%). In-hospital mortality was significantly higher in the CIN group 
than age and baseline serum creatinine matched controls. McCullough et al. (16) reported 
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an incidence of acute renal failure after coronary interventions of 14.5%. The in-hospital 
mortality rate for these patients was 7.1% but increased to 35.7% for patients who re-
quired dialysis. In our study, the mortality in patients who developed CIN was 40-fold 
greater than the non-CIN group (11.5 vs. 0.3%, respectively). Clearly, the strong associa-
tion between CIN and mortality in this study mirrors that in the PCI literature, and merits 
further investigation. 
 
Study Limitations 
This study is an analysis of observational data and conclusions are subject to the limita-
tions inherent in such reports. We found an association between CIN and adverse out-
come but cannot determine if the relationship is causal or casual. We conducted our anal-
ysis on a consecutive cohort of PVI patients with before and after PVI serum creatinine 
values. Approximately 43% of the overall cohort was not included in the analysis, with 
the majority due no post-PVI serum creatinine value available. While there were no sig-
nificant differences in characteristics between patients in whom before and after PVI se-
rum creatinine values were and were not available, it is possible that the rates of CIN in 
the overall cohort are either underestimated or overestimated. Although, the mean length 
of stay in non-CIN group was 3.8 days, some patients may have developed CIN after dis-
charge; therefore, CIN in this analysis is possibly under representing the true burden of 
CIN after PVI in this population. 
 
Conclusions 
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CIN is not uncommon following PVI and is strongly associated with the risk of in-
hospital death, MI, stroke, transfusion and increased length of stay. Clinical predictors of 
CIN include higher and lower body weight, diabetes, heart failure, anemia, baseline renal 
dysfunction, critical limb ischemia and a higher acuity of the PVI procedure. Exceeding a 
contrast volume of greater than three times the CCC was also strongly associated with 
CIN, and suggests the need to minimize contrast dose in patients undergoing PVI. Further 
studies are warranted to reduce CIN in patients undergoing PVI.  
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Figure Legend: 
Figure 1.Unadjusted and adjusted odds ratios and their 95% confidence intervals for ad-
verse outcomes comparing CIN vs. non-CIN. Frequencies, percentages for outcomes and 
p-values are from unadjusted numbers. P-values for adjusted odds ratio are the same as 
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those of unadjusted, except TIA or Stroke has p-value of 0.001. The blue vertical line is 
at 1.  
Figure 2. Pre-procedural and procedural risk factors for the development of acute kidney 
injury in this study. The development of acute kidney injury was strongly associated with 
adverse in hospital outcome. 
 
 
 
 
 
 
 
 
 
Table 1. Baseline Clinical Characteristics in CIN and Non-CIN group 
 
 
CIN group  
(n=400) N (%) 
Non-CIN group 
(n=12726) N (%) 
p value 
Age (SD) years 70.7 (±12.3) 69 (±11.4) 0.007 
Female (%) 200 (50) 5815 (45.7) 0.093 
BMI (SD) 29.3 (7.1) 28.4 (6.3) 0.01 
CAD (%) 277 (69.2) 7857 (61.7) 0.002 
Afib 93 (23.2) 1810 (14.2) <0.001 
Hyperlipidemia 336 (84) 11139 (87.5) 0.039 
HTN (%) 381 (95.2) 11696 (91.9)  0.014 
Anemia (%) 290 (72.5)  5410 (42.5) < 0.001 
Diabetes (%) 255 (63.7) 5764 (45.3) <0.001 
CHF (%) 2601 (20.4) 170 (42.5) <0.001 
CVD/TIA (%) 150 (37.5) 3707 (29.1) <0.001 
COPD 142 (35.5) 3563 (28) 0.001 
Anemia (%) 290 (72.5)  5410 (42.5) < 0.001 
CCC < 30 mL/min 61 (15.2) 561 (4.4) <0.001 
Indication    
 Claudication 224 (56) 9335 (73.4) <.001 
 Critical Limb ischemia 260 (65) 5304 (41.7) <.001 
Location    
 Upper extremity 9 (2.2) 420 (3.3) 0.316 
 Renal 14 (3.5) 329 (2.6) 0.262 
 Mesenteric 33 (8.2) 834 (6.6) 0.183 
 Lower extremity 348 (87) 11248 (88.4) 0.384 
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Aorto – iliac 100 (25) 3497 (27.5) 0.305 
 Femoral – popliteal 231 (57.8) 7345 (57.7) 1.0 
 Below knee 135 (33.8) 3047 (23.9) <0.001 
Pre-PVI Medicine    
 Aspirin 304 (76) 10574 (83.1) <.001 
 Clopidogrel 191 (47.8) 6228 (48.9) 0.648 
 Beta Blocker 285 (71.2) 8180 (64.3) 0.004 
 Ace Inhibitor 170 (42.5) 6031 (47.4) 0.06 
 Statin 279 (69.8) 9338 (73.4) 0.108 
 n-acetylcysteine 83 (20.8) 1331 (10.5) <.001 
Sodium Bicarbonate   
Infusion 
39 (9.8) 776 (6.1) 0.006 
 Saline Infusion 95 (23.8) 2646 (20.8) 0.151 
BMI = body mass index; CAD = coronary artery disease; Afib = atrial fibrillation; HTN 
= hypertension; CHF = congestive heart failure; CVD = cerebrovascular disease; TIA= 
transient ischemic attack; COPD= chronic obstructive pulmonary disease; CCC = calcu-
lated creatinine clearance. 
 
Table 2. Pre-PVI predictors for the development of post-PVI CIN by stepwise lo-
gistic regression. 
 
Name Odds Ratio (95% CI) P-value1 
Creatinine Clearance < 30 mL/mina 3.1 (2.1, 4.4) <.001 
Creatinine Clearance 30 – 60 mL/mina 1.2 (1, 1.6) 0.112 
Low BMI <18b 3.3 (1.2, 9) 0.024 
High BMI >30b 4.3 (1.5, 12.2) 0.006 
Pre Anemia 2 (1.6, 2.6) <.001 
Hyperlipidemia 0.8 (0.6, 1.1) 0.126 
Diabetes 1.8 (1.4, 2.3) <.001 
Prior CHF 1.7 (1.3, 2.1) <.001 
COPD 0.7 (0.5, 0.9) 0.002 
CVD or TIA 1.2 (1, 1.5) 0.123 
Prior PCI 1.4 (1.1, 1.7) 0.013 
Prior MI 1.3 (1, 1.6) 0.06 
Prior CABG 0.7 (0.5, 0.9) 0.012 
Aspirin (Pre procedure) 0.8 (0.6, 1) 0.101 
Ace Inhibitor (Pre procedure) 0.8 (0.7, 1) 0.096 
Critical Limb Ischemia 1.6 (1.2, 2.1) <.001 
Renal  1.8 (1.2, 2.7) 0.006 
Status – Urgentc 3 (2.4, 3.9) <.001 
Status – Emergentc 7.7 (4.9, 12.2) <.001 
Contrast/CCC Ratio > 3d 1.4 (1.1, 1.8) 0.003 
Model Assessment Measure 
Hosmer-Lemeshow P-value: 0.487; Area Under the ROC Curve (AUC): 0.786 
a. Reference is Creatinine clearance > 60 mL/min 
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b. Reference is Normal BMI (18 ≤ BMI ≤ 30) 
c. Reference is Elective 
d. Reference is Contrast/CCC ratio ≤ 3 
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Joic - Outcomes Plot JIC Fig 1 . 
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Joic central figure 2 . 
 
